Ascentage Pharma Group International
Ascentage Pharma Group International (ASPHF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Ascentage Pharma Group International (ASPHF), covering cash flow, earnings, and balance sheets.
Ascentage Pharma Group International (ASPHF) Income Statement & Financial Overview
View the income breakdown for Ascentage Pharma Group International ASPHF across both annual and quarterly reports.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $156.90M | $823.75M | $79.28M | $142.70M |
| Cost of Revenue | $14.03M | $15.06M | $12.39M | $18.15M |
| Gross Profit | $142.88M | $808.69M | $66.89M | $124.55M |
| Gross Profit Ratio | $0.91 | $0.98 | $0.84 | $0.87 |
| R&D Expenses | $503.17M | $444.08M | $397.16M | $309.81M |
| SG&A Expenses | $206.50M | $176.63M | $201.80M | $174.66M |
| Operating Expenses | $709.66M | $620.70M | $598.96M | $477.46M |
| Total Costs & Expenses | $723.69M | $635.76M | $611.35M | $495.62M |
| Interest Income | $0.00 | $0.00 | $16.96M | $46.69M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $37.57M | $41.60M | $39.40M | $39.78M |
| EBITDA | -$529.22M | $229.59M | -$492.67M | -$320.15M |
| EBITDA Ratio | -$3.37 | $0.28 | -$6.21 | -$2.24 |
| Operating Income | -$566.79M | $187.98M | -$532.07M | -$359.93M |
| Operating Income Ratio | -$3.61 | $0.23 | -$6.71 | -$2.52 |
| Other Income/Expenses (Net) | $8.64M | -$25.09M | -$1.19M | -$39.68M |
| Income Before Tax | -$558.15M | $162.90M | -$533.26M | -$399.60M |
| Income Before Tax Ratio | -$3.56 | $0.20 | -$6.73 | -$2.80 |
| Income Tax Expense | $10.36M | $69000.00 | $9.90M | $2.75M |
| Net Income | -$568.43M | $163.001M | -$523.29M | -$402.35M |
| Net Income Ratio | -$3.62 | $0.20 | -$6.60 | -$2.82 |
| EPS | -$1.82 | $0.55 | -$1.80 | -$1.47 |
| Diluted EPS | -$1.82 | $0.55 | -$1.80 | -$1.47 |
| Weighted Avg Shares Outstanding | $312.37M | $296.37M | $290.05M | $274.55M |
| Weighted Avg Shares Outstanding (Diluted) | $312.37M | $296.02M | $290.05M | $274.55M |
Over the past four quarters, Ascentage Pharma Group International demonstrated steady revenue growth, increasing from $142.70M in Q2 2023 to $156.90M in Q4 2024. Operating income reached -$566.79M in Q4 2024, maintaining a consistent -361% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at -$529.22M, reflecting operational efficiency. Net income dropped to -$568.43M, with EPS at -$1.82. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan